Skip to main content
British Heart Journal logoLink to British Heart Journal
. 1991 Sep;66(3):199–205. doi: 10.1136/hrt.66.3.199

Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study.

B Herrlin 1, O Nyquist 1, C Sylvén 1
PMCID: PMC1024644  PMID: 1931347

Abstract

OBJECTIVE--To study the long term effects (12 weeks) of enalapril on central haemodynamic function and on arterial oxygen content and its determinants--haemoglobin concentration and oxygen saturation--in patients with stable moderate heart failure. DESIGN--Double blind placebo controlled randomised study. PATIENTS--17 patients with stable moderate heart failure caused by dilated cardiomyopathy which was treated with diuretics and digoxin. METHODS--Central haemodynamic function, arterial oxygen content, arterial haemoglobin concentration, and arterial oxygen saturation were measured at rest and during submaximal exercise. Plasma volume and total body haemoglobin were determined at rest. RESULTS--With enalapril treatment heart rate, pulmonary capillary wedge pressure, mean arterial pressure, and systemic vascular resistance decreased significantly both at rest and during submaximal exercise. Cardiac output did not change at rest but tended to increase (p = 0.06) during submaximal exercise. Arterial oxygen saturation remained unchanged while haemoglobin concentration and arterial oxygen content were significantly reduced. Total body haemoglobin was significantly reduced but the plasma volume remained unchanged. At rest, the reduction in arterial oxygen content resulted in a significantly reduced mixed venous oxygen content. However, during submaximal exercise the increase in cardiac output fully compensated for the reduction in arterial oxygen content and this effect was indicated by the unaltered mixed venous oxygen content. No changes were found in the placebo group after twelve weeks. CONCLUSIONS--Enalapril unloads the heart and reduces haemoglobin concentration. During submaximal exercise, the improvement in systemic blood flow was counterbalanced by this negative effect on the oxygen carrying capacity and systemic oxygen delivery was unchanged.

Full text

PDF
199

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonaccio M. J., Kerwin L. Evidence for prejunctional inhibition of norepinephrine release by captopril in spontaneously hypertensive rats. Eur J Pharmacol. 1980 Nov 21;68(2):209–212. doi: 10.1016/0014-2999(80)90325-8. [DOI] [PubMed] [Google Scholar]
  2. Bauer C., Kurtz A. Oxygen sensing in the kidney and its relation to erythropoietin production. Annu Rev Physiol. 1989;51:845–856. doi: 10.1146/annurev.ph.51.030189.004213. [DOI] [PubMed] [Google Scholar]
  3. Borg G. A. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377–381. [PubMed] [Google Scholar]
  4. Bussmann W. D., Störger H., Hadler D., Reifart N., Fassbinder W., Jungmann E., Kaltenbach M. Long-term treatment of severe chronic heart failure with captopril: a double-blind, randomized, placebo-controlled, long-term study. J Cardiovasc Pharmacol. 1987;9 (Suppl 2):S50–S60. doi: 10.1097/00005344-198700002-00012. [DOI] [PubMed] [Google Scholar]
  5. Cleland J. G., Dargie H. J., Ball S. G., Gillen G., Hodsman G. P., Morton J. J., East B. W., Robertson I., Ford I., Robertson J. I. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J. 1985 Sep;54(3):305–312. doi: 10.1136/hrt.54.3.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cleland J. G., Dargie H. J. Heart failure, renal function, and angiotensin converting enzyme inhibitors. Kidney Int Suppl. 1987 May;20:S220–S228. [PubMed] [Google Scholar]
  7. Cleland J. G., Dargie H. J., Hodsman G. P., Ball S. G., Robertson J. I., Morton J. J., East B. W., Robertson I., Murray G. D., Gillen G. Captopril in heart failure. A double blind controlled trial. Br Heart J. 1984 Nov;52(5):530–535. doi: 10.1136/hrt.52.5.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cleland J. G., Gillen G., Dargie H. J. The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. Eur Heart J. 1988 Feb;9(2):132–141. doi: 10.1093/oxfordjournals.eurheartj.a062466. [DOI] [PubMed] [Google Scholar]
  9. Cohn J. N., Mashiro I., Levine T. B., Mehta J. Role of vasoconstrictor mechanisms in the control of left ventricular performance of the normal and damaged heart. Am J Cardiol. 1979 Oct 22;44(5):1019–1022. doi: 10.1016/0002-9149(79)90238-8. [DOI] [PubMed] [Google Scholar]
  10. Creager M. A., Massie B. M., Faxon D. P., Friedman S. D., Kramer B. L., Weiner D. A., Ryan T. J., Topic N., Melidossian C. D. Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. J Am Coll Cardiol. 1985 Jul;6(1):163–173. doi: 10.1016/s0735-1097(85)80269-2. [DOI] [PubMed] [Google Scholar]
  11. Drexler H., Banhardt U., Meinertz T., Wollschläger H., Lehmann M., Just H. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial. Circulation. 1989 Mar;79(3):491–502. doi: 10.1161/01.cir.79.3.491. [DOI] [PubMed] [Google Scholar]
  12. Dzau V. J., Hollenberg N. K. Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Ann Intern Med. 1984 Jun;100(6):777–782. doi: 10.7326/0003-4819-100-6-777. [DOI] [PubMed] [Google Scholar]
  13. Eckardt K. U., Bauer C. Erythropoietin in health and disease. Eur J Clin Invest. 1989 Apr;19(2):117–127. doi: 10.1111/j.1365-2362.1989.tb00205.x. [DOI] [PubMed] [Google Scholar]
  14. Eckardt K. U., Kurtz A., Bauer C. Regulation of erythropoietin production is related to proximal tubular function. Am J Physiol. 1989 May;256(5 Pt 2):F942–F947. doi: 10.1152/ajprenal.1989.256.5.F942. [DOI] [PubMed] [Google Scholar]
  15. Fan F. C., Chen R. Y., Schuessler G. B., Chien S. Effects of hematocrit variations on regional hemodynamics and oxygen transport in the dog. Am J Physiol. 1980 Apr;238(4):H545–H522. doi: 10.1152/ajpheart.1980.238.4.H545. [DOI] [PubMed] [Google Scholar]
  16. Fisher J. W., Samuels A. I., Langston J. W. Effects of angiotensin and renal artery constriction on erythropoietin production. J Pharmacol Exp Ther. 1967 Sep;157(3):618–625. [PubMed] [Google Scholar]
  17. Fouad F. M., Tarazi R. C., Bravo E. L., Hart N. J., Castle L. W., Salcedo E. E. Long-term control of congestive heart failure with captopril. Am J Cardiol. 1982 Apr 21;49(6):1489–1496. doi: 10.1016/0002-9149(82)90366-6. [DOI] [PubMed] [Google Scholar]
  18. Franciosa J. A., Wilen M. M., Jordan R. A. Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure. J Am Coll Cardiol. 1985 Jan;5(1):101–107. doi: 10.1016/s0735-1097(85)80090-5. [DOI] [PubMed] [Google Scholar]
  19. Fried W., Barone-Varelas J., Barone T., Anagnostou A. Effect of angiotensin infusion on extrarenal erythropoietin production. J Lab Clin Med. 1982 Apr;99(4):520–525. [PubMed] [Google Scholar]
  20. Fyhrquist F., Karppinen K., Honkanen T., Saijonmaa O., Rosenlöf K. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med. 1989 Oct;226(4):257–260. doi: 10.1111/j.1365-2796.1989.tb01390.x. [DOI] [PubMed] [Google Scholar]
  21. Giles T. D., Katz R., Sullivan J. M., Wolfson P., Haugland M., Kirlin P., Powers E., Rich S., Hackshaw B., Chiaramida A. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol. 1989 May;13(6):1240–1247. doi: 10.1016/0735-1097(89)90294-5. [DOI] [PubMed] [Google Scholar]
  22. Griffing G. T., Melby J. C. Enalapril (MK-421) and the white cell count and haematocrit. Lancet. 1982 Jun 12;1(8285):1361–1361. doi: 10.1016/s0140-6736(82)92430-8. [DOI] [PubMed] [Google Scholar]
  23. Hall J. E. Control of sodium excretion by angiotensin II: intrarenal mechanisms and blood pressure regulation. Am J Physiol. 1986 Jun;250(6 Pt 2):R960–R972. doi: 10.1152/ajpregu.1986.250.6.R960. [DOI] [PubMed] [Google Scholar]
  24. Hallman H., Farnebo L. O., Hamberger B., Johnsson G. A sensitive method for the determination of plasma catecholamines using liquid chromatography with electrochemical detection. Life Sci. 1978 Sep 11;23(10):1049–1052. doi: 10.1016/0024-3205(78)90665-3. [DOI] [PubMed] [Google Scholar]
  25. Hasking G. J., Esler M. D., Jennings G. L., Dewar E., Lambert G. Norepinephrine spillover to plasma during steady-state supine bicycle exercise. Comparison of patients with congestive heart failure and normal subjects. Circulation. 1988 Sep;78(3):516–521. doi: 10.1161/01.cir.78.3.516. [DOI] [PubMed] [Google Scholar]
  26. Hirakata H., Onoyama K., Hori K., Fujishima M. Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clin Nephrol. 1986 Jul;26(1):27–32. [PubMed] [Google Scholar]
  27. Ichikawa I., Kon V., Pfeffer M. A., Pfeffer J. M., Brenner B. M. Role of angiotensin II in the altered renal function of heart failure. Kidney Int Suppl. 1987 May;20:S213–S215. [PubMed] [Google Scholar]
  28. Kramer B. L., Massie B. M., Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation. 1983 Apr;67(4):807–816. doi: 10.1161/01.cir.67.4.807. [DOI] [PubMed] [Google Scholar]
  29. Kubo S., Nishioka A., Nishimura H., Kawamura K., Takatsu T. Effects of captopril on arterial and venous pressure, renal function, and humoral factors in severe chronic congestive heart failure. Clin Pharmacol Ther. 1984 Oct;36(4):456–463. doi: 10.1038/clpt.1984.204. [DOI] [PubMed] [Google Scholar]
  30. McGrath B. P., Arnolda L. F. Enalapril reduces the catecholamine response to exercise in patients with heart failure. Eur J Clin Pharmacol. 1986;30(4):485–487. doi: 10.1007/BF00607965. [DOI] [PubMed] [Google Scholar]
  31. McGrath B. P., Arnolda L., Matthews P. G., Jackson B., Jennings G., Kiat H., Johnston C. I. Controlled trial of enalapril in congestive cardiac failure. Br Heart J. 1985 Oct;54(4):405–414. doi: 10.1136/hrt.54.4.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mujais S. K., Fouad F. M., Textor S. C., Tarazi R. C., Bravo E. L., Hart N., Gifford R. W., Jr Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure. Br Heart J. 1984 Jul;52(1):63–71. doi: 10.1136/hrt.52.1.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Mulligan I. P., Fraser A. G., Tirlapur V., Lewis M. J., Newcombe R. G., Henderson A. H. A randomized cross-over study of enalapril in congestive heart failure: haemodynamic and hormonal effects during rest and exercise. Eur J Clin Pharmacol. 1988;34(4):323–331. doi: 10.1007/BF00542431. [DOI] [PubMed] [Google Scholar]
  34. Osborn J. L., Johns E. J. Renal neurogenic control of renin and prostaglandin release. Miner Electrolyte Metab. 1989;15(1-2):51–58. [PubMed] [Google Scholar]
  35. Patterson J. A., Naughton J., Pietras R. J., Gunnar R. M. Treadmill exercise in assessment of the functional capacity of patients with cardiac disease. Am J Cardiol. 1972 Nov;30(7):757–762. doi: 10.1016/0002-9149(72)90151-8. [DOI] [PubMed] [Google Scholar]
  36. RUSTAD H. CORRECTION FOR TRAPPED PLASMA IN MICRO-HEMATOCRIT DETERMINATIONS. Scand J Clin Lab Invest. 1964;16:677–679. doi: 10.3109/00365516409055233. [DOI] [PubMed] [Google Scholar]
  37. Sahn D. J., DeMaria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978 Dec;58(6):1072–1083. doi: 10.1161/01.cir.58.6.1072. [DOI] [PubMed] [Google Scholar]
  38. Saltin B., Kiens B., Savard G., Pedersen P. K. Role of hemoglobin and capillarization for oxygen delivery and extraction in muscular exercise. Acta Physiol Scand Suppl. 1986;556:21–32. [PubMed] [Google Scholar]
  39. Sharpe D. N., Murphy J., Coxon R., Hannan S. F. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation. 1984 Aug;70(2):271–278. doi: 10.1161/01.cir.70.2.271. [DOI] [PubMed] [Google Scholar]
  40. Sinoway L. I., Minotti J. R., Davis D., Pennock J. L., Burg J. E., Musch T. I., Zelis R. Delayed reversal of impaired vasodilation in congestive heart failure after heart transplantation. Am J Cardiol. 1988 May 1;61(13):1076–1079. doi: 10.1016/0002-9149(88)90129-4. [DOI] [PubMed] [Google Scholar]
  41. Sullivan M. J., Higginbotham M. B., Cobb F. R. Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects. Circulation. 1988 Sep;78(3):506–515. doi: 10.1161/01.cir.78.3.506. [DOI] [PubMed] [Google Scholar]
  42. Timmis A. D., Bojanowski L. M., Najm Y. C., Nelson D. J., Gosling R. G. Captopril versus placebo in congestive heart failure: effects on oxygen delivery to exercising skeletal muscle. Eur Heart J. 1987 Dec;8(12):1295–1304. doi: 10.1093/oxfordjournals.eurheartj.a062216. [DOI] [PubMed] [Google Scholar]
  43. Webster M. W., Fitzpatrick M. A., Hamilton E. J., Nicholls M. G., Ikram H., Espiner E. A., Wells J. E. Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure. Drugs. 1985;30 (Suppl 1):74–81. doi: 10.2165/00003495-198500301-00011. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES